Trenzyme

Trenzyme

Konstanz, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $500K

Overview

Trenzyme is a privately held, revenue-generating German CRO specializing in customized cell culture and protein production services. With over two decades of operation, the company has established itself as a reliable partner for R&D outsourcing, leveraging scientific expertise and a modular, ISO9001-certified service model to accelerate client innovation. Its core value proposition lies in offering flexible, project-specific solutions from DNA to stable cell lines or purified proteins, saving clients time and resources.

AntibodiesBiologics

Technology Platform

Modular service platform for customized cell line development (including iPSC differentiation) and recombinant protein production, utilizing a range of expression systems and ISO9001-certified processes.

Funding History

1
Total raised:$500K
Grant$500K

Opportunities

The growing trend of R&D outsourcing in biopharma and the expansion of the iPSC and complex biologics markets present significant growth opportunities.
Trenzyme can capitalize on this by expanding its service portfolio and leveraging its long-term expertise to form deeper partnerships with clients.

Risk Factors

Key risks include dependence on the broader biopharma R&D funding climate, intense competition from other CROs, key-person dependency on the founder/CSO, and the need for continual investment to avoid technological obsolescence.

Competitive Landscape

Trenzyme competes in a fragmented global market of life science CROs, ranging from large, full-service organizations to small, niche providers. Its differentiation is based on high customization, scientific expertise in specific areas like iPSCs, and a client-centric communication model, rather than competing solely on scale or price.